|
Deferred Research And Development Arrangement (Details) (USD $)
|
3 Months Ended | 6 Months Ended | 12 Months Ended | 6 Months Ended | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Jun. 30, 2014
|
Dec. 31, 2013
|
Jun. 30, 2014
Rexgene [Member]
|
Jun. 30, 2013
Rexgene [Member]
|
Jun. 30, 2014
Rexgene [Member]
|
Jun. 30, 2013
Rexgene [Member]
|
Dec. 31, 2003
Rexgene [Member]
|
Dec. 31, 2013
Rexgene [Member]
|
Jun. 30, 2014
Teva Pharmaceutical Industries, Ltd. [Member]
|
Jun. 30, 2013
Teva Pharmaceutical Industries, Ltd. [Member]
|
Dec. 31, 2013
Teva Pharmaceutical Industries, Ltd. [Member]
|
Nov. 27, 2012
Teva Pharmaceutical Industries, Ltd. [Member]
|
|
| Research and Development Arrangement, Contract to Perform for Others [Line Items] | ||||||||||||
| Research and development arrangement, one-time fee | $ 1,500,000 | |||||||||||
| Reduction of research and development expenses | 18,750 | 18,750 | 37,500 | 37,500 | 117,974 | 344,621 | ||||||
| research and development period | 20 years | |||||||||||
| Deferred Research and Development Arrangement | 678,156 | 833,630 | 637,500 | 637,500 | 675,000 | 40,656 | 158,630 | |||||
| Royalties paid, percentage of net sales | 3.00% | |||||||||||
| Restricted Cash and Cash Equivalents, Noncurrent | $ 78,156 | $ 196,130 | $ 926,000 | |||||||||